Alnylam Pharmaceuticals Inc
LSE:0HD2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Alnylam Pharmaceuticals Inc
LSE:0HD2
|
US |
|
Greif Inc
F:GB6B
|
US |
|
G
|
General Mills Inc
F:GRM
|
US |
Wall St Price Targets
0HD2 Price Targets Summary
Alnylam Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for 0HD2 is 456.14 USD with a low forecast of 239.31 USD and a high forecast of 596.67 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0HD2's stock price target?
Price Target
456.14
USD
According to Wall Street analysts, the average 1-year price target for 0HD2 is 456.14 USD with a low forecast of 239.31 USD and a high forecast of 596.67 USD.
What is the Revenue forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
34%
Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 3 years is 34%.
What is the Gross Profit forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
31%
The compound annual growth rate for Gross Profit over the next 3 years is 31%.
What is the Operating Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
72%
The compound annual growth rate for Operating Income over the next 3 years is 72%.
What is the Pre-Tax Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
93%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 93%.
What is the Net Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
87%
The compound annual growth rate for Net Income over the next 3 years is 87%.
